Trial Profile
A Prospective Safety, Tolerance, Pharmacodynamics and Pharmacokinetics Study of Sobetirome in Male Subjects Diagnosed With X-linked Adrenoleukodystrophy (X-ALD)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sobetirome (Primary)
- Indications Adrenoleucodystrophy; Adrenomyeloneuropathy
- Focus Pharmacokinetics
- 16 Sep 2014 New trial record